Portal de Periódicos da CAPES

Neuroimaging in neuropsychiatric systemic lupus erythematosus

1999; Wiley; Volume: 42; Issue: 10 Linguagem: Inglês

10.1002/1529-0131(199910)42

1529-0131

Wilmer L. Sibbitt, Randy R. Sibbitt, William M. Brooks,

Multiple Sclerosis Research Studies

Arthritis & RheumatismVolume 42, Issue 10 p. 2026-2038 Special ArticleFree to Read Neuroimaging in neuropsychiatric systemic lupus erythematosus Wilmer L. Sibbitt Jr., Corresponding Author Wilmer L. Sibbitt Jr. University of New Mexico Health Sciences Center, Albuquerque, NMDepartment of Internal Medicine, Division of Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM 87131Search for more papers by this authorRandy R. Sibbitt, Randy R. Sibbitt St. Peter's Hospital, Helena, MontanaSearch for more papers by this authorWilliam M. Brooks, William M. Brooks University of New Mexico Health Sciences Center, Albuquerque, NMSearch for more papers by this author Wilmer L. Sibbitt Jr., Corresponding Author Wilmer L. Sibbitt Jr. University of New Mexico Health Sciences Center, Albuquerque, NMDepartment of Internal Medicine, Division of Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM 87131Search for more papers by this authorRandy R. Sibbitt, Randy R. Sibbitt St. Peter's Hospital, Helena, MontanaSearch for more papers by this authorWilliam M. Brooks, William M. Brooks University of New Mexico Health Sciences Center, Albuquerque, NMSearch for more papers by this author First published: 26 April 2001 https://doi.org/10.1002/1529-0131(199910)42:10 3.0.CO;2-JCitations: 134AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Adelman DC, Saltiel E, Klinenberg JR. The neuropsychiatric manifestations of systemic lupus erythematosus: an overview. Semin Arthritis Rheum 1986; 15: 185–99. 2 Bluestein HG. Neuropsychiatric manifestations of systemic lupus erythematosus. N Engl J Med 1987; 317: 309–11. 3 McNicholl JM, Glynn D, Mongey AB, Hutchinson M, Bresnihan B. A prospective study of neurophysiologic, neurologic and immunologic abnormalities in systemic lupus erythematosus. J Rheumatol 1994; 21: 1061–106. 4 Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19: 47–52. 5 Gibson T, Myers AR. Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 1975; 35: 398–406. 6 Ginzler EM, Schorn K. Outcome and prognosis in systemic lupus erythematosus. Rheum Dis Clin North Am 1988; 14: 67–78. 7 Ginzler EM. Clinical manifestations of disease activity, its measurement, and associated morbidity in systemic lupus erythematosus. Curr Opin Rheumatol 1991; 3: 780–8. 8 Van Dam AP. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 1991; 11: 1–11. 9 Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996; 156: 1337–44. 10 Mitsias P, Levine SR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology 1994; 44: 385–93. 11 Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174: 357–64. 12 Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992; 19: 562–7. 13 Sibbitt WL Jr, Haseler LJ, Griffey RH, Hart BL, Sibbitt RR, Matwiyoff NA. Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. AJNR Am J Neuroradiol 1994; 15: 923–8. 14 Sibbitt WL Jr, Brooks WM. When neuropsychiatric symptoms complicate SLE. J Musculoskel Med 1997; 14: 31–41. 15 Brooks WM, Jung RE, Ford CC, Greinel EJ, Sibbitt WL Jr. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999; 26: 81–5. 16 Kovacs JA, Urowitz MB, Gladman DD. Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 1993; 19: 795–814. 17 West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20: 129–58. 18 Singer J, Denburg JA, and the Ad Hoc Neuropsychiatric Lupus Workshop Group. Diagnostic criteria for neuropsychiatric systemic lupus erythematosus: the results of a consensus meeting. J Rheumatol 1990; 17: 1397–402. 19 Denburg SD, Denburg JA, Carbotte RM, Fisk JD, Hanly JG. Cognitive deficits in systemic lupus erythematosus. Rheum Dis Clin North Am 1993; 19: 815–31. 20 Bluestein HG. The central nervous system in systemic lupus erythematosus. In: RG Lahita, editor. Systemic lupus erythematosus. New York: Churchill Livingstone; 1992. p. 639. 21 Carbotte RM, Denburg SD, Denburg JA, Nahmias C, Garnett ES. Fluctuating cognitive abnormalities and cerebral glucose metabolism in neuropsychiatric systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1992; 55: 1054–9. 22 ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608. 23 Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus: a clinical-pathological study of 24 cases and review of the literature. Medicine (Baltimore) 1968; 47: 337–69. 24 Ellis SG, Verity MA. Central nervous systemic involvement in systemic lupus erythematosus: a review of neuropathological findings in 57 cases, 1955–1977. Semin Arthritis Rheum 1979; 8: 212–21. 25 Funata N. Cerebral vascular changes in systemic lupus erythematosus. Bull Tokyo Med Dent Univ 1979; 26: 91–112. 26 Ellison D, Gatter K, Heryet A, Esiri M. Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus. J Clin Pathol 1993; 46: 37–40. 27 Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19: 732–41. 28 Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992; 35: 417–22. 29 Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988; 23: 380–4. 30 Hughson MD, McCarty GA, Sholer CM, Brumback RA. Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome. Mod Pathol 1993; 6: 644–53. 31 Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40: 1181–9. 32 Shintaku M, Matsumoto R. Disseminated perivenous necrotizing encephalomyelitis in systemic lupus erythematosus: report of an autopsy case. Acta Neuropathol (Berl) 1998; 95: 313–7. 33 Bruyn GA. Controversies in lupus: nervous system involvement. Ann Rheum Dis 1995; 54: 159–67. 34 Hammad A, Tsukada Y, Torre N. Cerebral occlusive vasculopathy in systemic lupus erythematosus and speculation on the part played by complement. Ann Rheum Dis 1992; 51: 550–2. 35 Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39: 9–22. 36 Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988; 31: 632–41. 37 Sibbitt WL Jr, Brooks WM, Haseler LJ, Griffey RH, Frank LM, Hart BL, et al. Spin-spin relaxation of brain tissues in systemic lupus erythematosus: a method for increasing the sensitivity of magnetic resonance imaging for neuropsychiatric lupus. Arthritis Rheum 1995; 38: 810–8. 38 Raymond AA, Zariah AA, Samad SA, Chin CN, Kong NC. Brain calcification in patients with cerebral lupus. Lupus 1996; 5: 123–8. 39 Reiff A, Miller J, Shaham B, Bernstein B, Szer IS. Childhood central nervous system lupus: longitudinal assessment using single photon emission computed tomography. J Rheumatol 1997; 24: 2461–5. 40 Gaylis NB, Altman RD, Ostrov S, Quencer R. The selective value of computed tomography of the brain in cerebritis due to systemic lupus erythematosus. J Rheumatol 1982; 9: 850–4. 41 Carette S, Urowitz MB, Grosman H, St. Louis EL. Cranial computerized tomography in systemic lupus erythematosus. J Rheumatol 1982; 9: 855–9. 42 Vermess M, Bernstein RM, Bydder GM, Steiner RE, Young IR, Hughes GR. Nuclear magnetic resonance (NMR) imaging of the brain in systemic lupus erythematosus. J Comput Assist Tomogr 1983; 7: 461–7. 43 Brant-Zawadski M, Mills CM, Norma D. Central nervous system. In: AR Margulis, CB Higgins, L Kaufman, editors. Clinical magnetic resonance imaging. San Francisco: Radiology and Research and Education Foundation; 1983. p. 91. 44 Futran J, Shore A, Urowitz MB, Grossman H. Subdural hematoma in systemic lupus erythematosus: report and review of the literature. J Rheumatol 1987; 14: 378–83. 45 Shah ZR, Bellon EM, Toor AH, Shields R. CT demonstration of brain infarcts due to deep venous thrombosis in systemic lupus erythematosus. Comput Med Imaging Graph 1988; 12: 241–7. 46 Garcia Raya P, Gil Aguado A, Simon Merlo MJ, Lavilla Uriol P, Vega Astudillo A, Garcia Puig J. Massive cerebral calcification in systemic lupus erythematosus: report of an unusual case. Lupus 1994; 3: 133–5. 47 Szer IS, Miller JH, Rawlings D, Shaham B, Bernstein B. Cerebral perfusion abnormalities in children with central nervous system manifestations of lupus detected by single photon emission computed tomography. J Rheumatol 1993; 20: 2143–8. 48 Shapeero LG, Norman A. Imaging of systemic lupus erythematosus. In: RG Lahita, editor. Systemic lupus erythematosus. 2nd ed. New York: Churchill Livingstone; 1992. p. 447–526. 49 Kovacs JA, Urowitz MB, Gladman DD, Zeman R. The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. J Rheumatol 1995; 22: 1247–53. 50 Miguel EC, Pereira RM, Pereira CA, Baer L, Gomes RE, de Sa LC, et al. Psychiatric manifestations of systemic lupus erythematosus: clinical features, symptoms, and signs of central nervous system activity in 43 patients. Medicine (Baltimore) 1994; 73: 224–32. 51 Bentson J, Rezon M, Winters J, Wilson G. Steroids and apparent cerebral atrophy on computed tomography scans. J Comput Assist Tomogr 1978; 2: 16–23. 52 Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494–500. 53 Shintani S, Ono K, Hinoshita H, Shiigai T, Tsuruoka S. Unusual neuroradiological findings in systemic lupus erythematosus. Eur Neurol 1993; 33: 13–6. 54 Ogura N, Atsumi T, Sagawa A, Jodo S, Amasaki Y, Nakabayashi T, et al. Systemic lupus erythematosus associated with benign intracranial hypertension: a case report. Ryumachi 1992; 32: 66–72. 55 Grigor R, Edmonds J, Lekonia R, Bresnihan B, Hughes GR. Systemic lupus erythematosus: a prospective analysis. Ann Rheum Dis 1978; 37: 121–8. 56 Feinglass EJ, Arnett FC, Dorsch CA, Zizic M, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 1976; 55: 323–39. 57 Shahar E, Goshen E, Tauber Z, Lahat E. Parkinsonian syndrome complicating systemic lupus erythematosus. Pediatr Neurol 1998; 18: 456–8. 58 Horoshovski D, Amital H, Katz M, Shoenfeld Y. Pseudotumour cerebri in SLE. Clin Rheumatol 1995; 14: 708–10. 59 Nampoory MR, Johny KV, Gupta RK, Constandi JN, Nair MP, al-Muzeiri I. Treatable intracranial hypertension in patients with lupus nephritis. Lupus 1997; 6: 597–602. 60 Aisen AM, Gabrielsen TO, McCune WJ. MR imaging of systemic lupus erythematosus involving the brain. AJR Am J Roentgenol 1985; 144: 1027–31. 61 Sibbitt WL Jr, Sibbitt RR, Griffey RH, Eckel C, Bankhurst AD. Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 1014–22. 62 Kirk A, Kertesz A, Polk MJ. Dementia with leukoencephalopathy in systemic lupus erythematosus. Can J Neurol Sci 1991; 18: 344–8. 63 Bradley WG, Bydder GM. Advanced MR imaging techniques. St. Louis: Mosby; 1997. 64 Trevor RP, Sondheimer FK, Fessel WJ. Angiographic demonstration of major cerebral vessel occlusion in systemic lupus erythematosus. Neuroradiology 1972; 4: 202–7. 65 Sakaki T, Morimoto T, Utsumi S. Cerebral transmural angiitis and ruptured cerebral aneurysms in patients with systemic lupus erythematosus. Neurochirurgia 1990; 33: 132–5. 66 Wood ML, Wehrli FW. Principles of magnetic resonance imaging. In: DD Stark, WG Bradley, editors. Magnetic resonance imaging. 2nd ed. St. Louis: Mosby; 1999. p. 1–14. 67 McCune WJ, MacGuire A, Aisen A, Gebarski S. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum 1988; 31: 159–66. 68 Stimmler MM, Coletti PM, Quismorio FP Jr. Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 1993; 22: 335–49. 69 Boumpas DT, Patronas AJ, Dalakas MC, Hakim CA, Klippel JH, Balow JE. Acute transverse myelitis in systemic lupus erythematosus: magnetic resonance imaging and review of the literature. J Rheumatol 1990; 17: 89–92. 70 Robbins ML, Kornguth SE, Bell CL, Kalinke T, England D, Turski P, et al. Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus: combination with anticardiolipin antibody assay and magnetic resonance imaging. Arthritis Rheum 1988; 31: 623–31. 71 Jarek MJ, West SG, Baker MR, Rak KM. Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus. Arthritis Rheum 1994; 37: 1609–13. 72 Brooks WM, Sabet A, Sibbitt WL Jr, Barker PB, van Zijl PC, Duyn JH, et al. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J Rheumatol 1997; 24: 2323–9. 73 Rozell CL, Sibbitt WL Jr, Brooks WM. Structural and neurochemical markers of brain injury in the migraine diathesis of systemic lupus erythematosus. Cephalalgia 1998; 18: 209–15. 74 Friedman SD, Stidley CA, Brooks WM, Hart BL, Sibbitt WL Jr. Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. Radiology 1998; 209: 79–84. 75 Hachulla E, Michon-Pasturel U, Leys D, Pruvo JP, Queyrel V, Masy E, et al. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies. Lupus 1998; 7: 124–31. 76 Ishikawa O, Ohnishi K, Miyachi Y, Ishizaka H. Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging: relationship to anticardiolipin antibody. J Rheumatol 1994; 21: 87–90. 77 Sabet A, Sibbitt WL Jr, Stidley CA, Danska J, Brooks WM. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998; 29: 2254–60. 78 Jacobs L, Kinkel PR, Costello PB, Alukal MK, Kinkel WR, Green FA. Central nervous system lupus erythematosus: the value of magnetic resonance imaging. J Rheumatol 1988; 15: 601–6. 79 Chinn RJS, Wilkinson ID, Hall-Craggs MA, Paley MNJ, Shortall E, Carter S, et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 36–46. 80 Moody DM, Bell MA, Challa VR. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. AJNR Am J Neuroradiol 1990; 11: 431–9. 81 Falcini F, De Cristofaro MT, Ermini M, Guarnieri M, Massai G, Olmastroni M, et al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: a prospective SPECT study. Single photon emission computed tomography. J Rheumatol 1998; 25: 583–8. 82 Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998; 41: 41–7. 83 Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am J Roentgenol 1996; 167: 1573–8. 84 Davie CA, Feinstein A, Kartsounis LD, Barker GJ, McHugh NJ, Walport MJ, et al. Proton magnetic resonance spectroscopy of systemic lupus erythematosus involving the central nervous system. J Neurol 1995; 242: 522–58. 85 Colamussi P, Giganti M, Cittanti C, Dovigo L, Trotta F, Tola MR, et al. Brain single-photon emission tomography with 99mTc-HMPAO in neuropsychiatric systemic lupus erythematosus: relations with EEG and MRI findings and clinical manifestations. Eur J Nucl Med 1995; 22: 17–24. 86 McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995; 58: 548–54. 87 Otte A, Weiner SM, Peter HH, Mueller-Brand J, Goetze M, Moser E, et al. Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study. Eur J Nucl Med 1997; 24: 787–91. 88 Lin WY, Wang SJ, Yen TC, Lan JL. Technetium-99m-HMPAO brain SPECT in systemic lupus erythematosus with CNS involvement. J Nucl Med 1997; 38: 1112–5. 89 McAbee GN, Barasch ES. Resolving MRI lesions in lupus erythematosus selectively involving the brainstem. Pediatr Neurol 1990; 6: 186–9. 90 Miller DH, Buchanan N, Barker G, Morrissey SP, Kendall BE, Rudge P, et al. Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus. J Neurol 1992; 239: 460–4. 91 Colamussi P, Trotta F, Ricci R, Cittanti C, Govoni M, Barbarella G, et al. Brain perfusion SPET and proton magnetic resonance spectroscopy in the evaluation of two systemic lupus erythematosus patients with mild neuropsychiatric manifestations. Nucl Med Commun 1997; 18: 269–73. 92 Petropoulos H, Sibbitt WL Jr, Brooks WM. Automated T2 quantitation in neuropsychiatric lupus erythematosus: a marker of active disease. J Magn Reson Imaging 1999; 9: 39–43. 93 Sibbitt WL Jr, Sibbitt RR. Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 1993; 19: 851–68. 94 Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II. Experimental comparison and preliminary results. Magn Reson Med 1996; 36: 726–36. 95 Runge VM, Kirsch JE, Wells JW, Dunworth JN, Hilaire L, Woolfolk CE. Repeat cerebral blood volume assessment with first-pass MR imaging. J Magn Reson Imaging 1994; 4: 457–61. 96 Bell CL, Partington C, Robbins M, Graziano F, Turski P, Kornguth S. Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus: correlation with clinical remission and antineurofilament and anticardiolipin antibody titers. Arthritis Rheum 1991; 34: 432–41. 97 West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995; 99: 153–63. 98 Hanly JG, Walsh NM, Fisk JD, Eastwood B, Hong C, Sherwood G, et al. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br J Rheumatol 1993; 32: 291–6. 99 Kinoshita M, Iwana K, Shinoura H, Aotsuka S, Sumiya M. Progressive multifocal leukoencephalopathy resembling central nervous system systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 313–5. 100 Iles RA, Stevens AN, Griffiths JR. NMR studies of metabolites in living tissue. Prog NMR Spectrosc 1982; 15: 49–56. 101 Chan L. The current status of magnetic resonance spectroscopy—basic and clinical aspects. West J Med 1985; 143: 773–81. 102 Gadian DG. Nuclear magnetic resonance and its applications to living systems. 2nd ed. New York: Oxford University Press; 1995. 103 Matson GB, Weiner MW. Spectroscopy. In: DD Stark, WG Bradley Jr, editors. Magnetic resonance imaging. St. Louis: Mosby; 1999. p. 181. 104 Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 1994; 10: 191–247. 105 Hennig J, Pfister H, Ernst T, Ott D. Direct absolute quantification of metabolites in the human brain with in vivo localized proton spectroscopy. NMR Biomed 1992; 5: 193–9. 106 Barker PB, Soher BJ, Blackband SJ, Chatham JC, Mathews VP, Bryan RN. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration standard. NMR Biomed 1993; 6: 89–94. 107 Alger JR, Symko SC, Bizzi A, Posse S, DesPres DJ, Armstrong MR. Absolute quantitation of short TE brain 1H-MR spectra and spectroscopic imaging data. J Comput Assist Tomogr 1993; 17: 191–9. 108 Brooks WM, Friedman SD, Stidley CA. Reproducibility of 1H-MRS in vivo. Magn Reson Med 1999; 41: 193–7. 109 Koller KJ, Zaczek R, Coyle JT. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 1984; 43: 1136–42. 110 Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49–58. 111 Sappey-Marinier D, Calabrese G, Hetherington HP, Fisher SN, Deicken R, van Dyke C, et al. Proton magnetic resonance spectroscopy of human brain: applications to normal white matter, chronic infarction, and MRI white matter signal hyperintensities. Magn Reson Med 1992; 26: 313–27. 112 Meyerhoff DJ, MacKay S, Poole N, Dillon WP, Weiner MW, Fein G. N-acetylaspartate reductions measured by 1H MRSI in cognitively impaired HIV-seropositive individuals. Magn Reson Imaging 1994; 12: 653–9. 113 Ford CC, Griffey RH, Matwiyoff NA, Rosenberg GA. Multivoxel 1H-MRS of stroke. Neurology 1992; 42: 1408–12. 114 Narayana PA, Wolinsky JS, Jackson EF, McCarthy M. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imaging 1992; 2: 263–70. 115 Haseler LJ, Sibbitt WL Jr, Sibbitt RR, Hart BL. Neurologic, MR imaging, and MR spectroscopic findings in eosinophilia myalgia syndrome. AJNR Am J Neuroradiol 1998; 19: 1687–94. 116 Haseler LJ, Sibbitt WL Jr, Mojtahedzadeh HN, Reddy S, Agarwal VP, McCarthy DM. Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during oral lactulose therapy. AJNR Am J Neuroradiol 1998; 19: 1681–6. 117 Friedman SD, Brooks WM, Jung RE, Hart BL, Yeo RA. Proton MR spectroscopic findings correspond to neuropsychological function in traumatic brain injury. AJNR Am J Neuroradiol 1998; 19: 1879–85. 118 Friedman SD, Brooks WM, Jung RE, Chiulli SJ, Sloan JH, Montoya BT, et al. Quantitative proton MRS predicts outcome after traumatic brain injury. Neurology 1999; 52: 1384–91. 119 Sibbitt WL Jr, Haseler LJ, Griffey RR, Friedman SD, Brooks WM. Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. AJNR Am J Neuroradiol 1997; 18: 1271–7. 120 Mortilla M, Ermini M, Nistri M, Dalpozzo G, Falcini F. MRI and proton spectroscopy of the brain in pediatric onset SLE. Riv Neuroradiol 1997; 10: 28–30. 121 Oberhaensli RD, Galloway GJ, Hilton-Jones D, Bore PJ, Styles P, Rajagopalan B, et al. The study of human organs by phosphorus-31 topical magnetic resonance spectroscopy. Br J Radiol 1987; 60: 367–73. 122 Radda GK, Oberhaensli RD, Taylor DJ. The biochemistry of human diseases as studied by 31P NMR in man and animal models. Ann N Y Acad Sci 1987; 508: 300–8. 123 Glonek T, Kopp SJ, Kot E, Pettegrew JW, Harrison WH, Cohen MM. P-31 nuclear magnetic resonance analysis of brain: the perchloric acid extract spectrum. J Neurochem 1982; 39: 1210–9. 124 Griffey RH, Brown MS, Bankhurst AD, Sibbitt RR, Sibbitt WL Jr. Depletion of high-energy phosphates in the central nervous system of patients with systemic lupus erythematosus, as determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Arthritis Rheum 1990; 33: 827–33. 125 Miatto O, Gonzalez RG, Buonanno F, Growdon JH. In vitro 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease. Can J Neurol Sci 1986; 13: 535–9. 126 James TL, Chang LH, Chew W, Gonzalez-Mendez R, Litt L, Mills P, et al. In situ brain metabolism. Ann N Y Acad Sci 1987; 508: 64–80. 127 Chance B, Leigh JS Jr, Nioka S, Sinwell T, Younkin D, Smith DS. An approach to the problem of metabolic heterogeneity in brain: ischemia and reflow after ischemia. Ann N Y Acad Sci 1987; 508: 309–20. 128 Ritchlin CT, Chabot RJ, Alper K, Buyon J, Belmont HM, Roubey R, et al. Quantitative electroencephalography: a new approach to the diagnosis of cerebral dysfunction in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 1330–42. 129 Nobili F, Rodriguez G, Arrigo A, Stubinski BM, Rossi E, Cerri R, et al. Accuracy of 133-xenon regional cerebral blood flow and quantitative electroencephalography in systemic lupus erythematosus. Lupus 1996; 5: 93–102. 130 Abou-Khalil B, Fakhoury T, Jennings M, Moots P, Warner J, Kessler RM. Inhibitory motor seizures: correlation with centroparietal structural and functional abnormalities. Acta Neurol Scand 1995; 91: 103–8. 131 Rodriguez G, Nobili F, Rocca G, De Carli F, Gianelli MV, Rosadini G. Quantitative electroencephalography and regional cerebral blood flow: discriminant analysis between Alzheimer's patients and healthy controls. Dement Geriatr Cogn Disord 1998; 9: 274–83. 132 Rodriguez G, Nobili F, Arrigo A, Priano F, De Carli F, Francione S, et al. Prognostic significance of quantitative electroencephalography in Alzheimer patients: preliminary observations. Electroencephalogr Clin Neurophysiol 1996; 99: 123–8. 133 Bennahum DA, Messner RP, Shoop JD. Brain scan findings in central nervous system involvement by lupus erythematosus. Ann Intern Med 1974; 81: 763–5. 134 Tan RF, Gladman DD, Urowitz MB, Milne N. Brain scan diagnosis of central nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 1978; 37: 357–62. 135 Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979; 44: 127–37. 136 Frackowiak RS, Lenzi GL, Jones T, Heather JD. Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. J Comput Assist Tomogr 1980; 4: 727–36. 137 Herscovitch P, Markham J, Raichle ME. Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. J Nucl Med 1983; 24: 782–9. 138 Koeppe RA, Holden JE, Polcyn RE, Nickles RJ, Hutchins GD, Weese JL. Quantitation of local cerebral blood flow and partition coefficient without arterial sampling: theory and validation. J Cereb Blood Flow Metab 1985; 5: 214–23. 139 Holman BL. Functional imaging in systemic lupus erythematosus: an accurate indicator of central nervous system involvement? Arthritis Rheum 1993; 36: 1193–5. 140 Pinching AJ, Travers RL, Hughes GR, Jones T, Moss S. Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet 1978; 1: 898–900. 141 Stoppe G, Wildhagen K, Seidel JW, Meyer GJ, Schober O, Heintz P, et al. Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology 1990; 40: 304–8. 142 Meyer GJ, Schober O, Stoppe G, Wildhagen K, Seidel JW, Hundeshagen H. Cerebral involvement in systemic lupus erythematosus (SLE): comparison of positron emission tomography (PET) with other imaging methods. Psychiatry Res 1989; 29: 367–8. 143 Guttman M, Lang AE, Garnett ES, Nahmias C, Firnau G, Tyndel FJ, et al. Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea. Mov Disord 1987; 2: 201–10. 144 Hiraiwa M, Nonaka C, Abe T, Iio M. Positron emission tomography in systemic lupus erythematosus: relation of cerebral vasculitis to PET findings. AJNR Am J Neuroradiol 1983; 4: 541–3. 145 Otte A, Weiner SM, Hoegerle S, Wolf R, Juengling FD, Peter HH, et al. Neuropsychiatric systemic lupus erythematosus before and after immunosuppressive treatment: a FDG PET study. Lupus 1998; 7: 57–9. 146 Feeney DM, Baron JC. Diaschisis. Stroke 1986; 17: 817–30. 147 Powers WJ. Positron emission tomography in the evaluation of cerebrovascular disease: clinical applications? In: WH Theodore, editor. Clinical neuroimaging. New York: Alan R. Liss; 1988. p. 49. 148 Herscovitch P, Auchus AP, Gado M, Chi D, Raichle ME. Correction of positron emission tomography data for cerebral atrophy. J Cereb Blood Flow Metab 1986; 6: 120–4. 149 Bednarczyk EM, Remler B, Weikart C, Nelson AD, Reed RC. Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache. Neurology 1998; 50: 1736–40. 150 Sadzot B, Maquet P, Franck G. Is positron emission tomography a useful tool for studying migraine? Cephalalgia 1995; 15: 316–22. 151 Olesen J, Friberg L, Olsen TS, Andersen AR, Lassen NA, Hansen PE, et al. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain 1993; 116: 187–202. 152 George MS, Ketter TA, Post RM. SPECT and PET imaging in mood disorders. J Clin Psychiatry 1993; 54 Suppl: 6–13. 153 Ferrie CD, Maisey M, Cox T, Polkey C, Barrington SF, Panayiotopoulos CP, et al. Focal abnormalities detected by 18FDG PET in epileptic encephalopathies. Arch Dis Child 1996; 75: 102–7. 154 Sailer M, Burchert W, Ehrenheim C, Smid HG, Haas J, Wildhagen K, et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997; 244: 186–93. 155 Sharp PF, Smith FW, Gemmell HG, Lyall D, Evans NT, Gvozdanovic D, et al. Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med 1986; 27: 171–7. 156 Obrist WD, Thompson HK Jr, Wang HS, Wilkinson WE. Regional cerebral blood flow estimated by 133-xenon inhalation. Stroke 1975; 6: 245–56. 157 Kushner MJ, Chawluk J, Fazekas F, Mandell B, Burke A, Jaggi J, et al. Cerebral blood flow in systemic lupus erythematosus with or without cerebral complications. Neurology 1987; 37: 1596–8. 158 Awada HH, Mamo HL, Luft AG, Ponsin JC, Kahn MF. Cerebral blood flow in systemic lupus erythematosus with and without central nervous system involvement. J Neurol Neurosurg Psychiatry 1987; 50: 1597–601. 159 Rogers MP, Waterhouse E, Nagel JS, Roberts NW, Stern SH, Fraser P, et al. I-123 iofetamine SPECT scan in systemic lupus erythematosus patients with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus 1992; 1: 215–9. 160 Grunwald F, Schomburg A, Badali A, Ruhlmann J, Pavics L, Biersack HJ. 18FDG PET and acetazolamide-enhanced 99mTc-HMPAO SPET in systemic lupus erythematosus. Eur J Nucl Med 1995; 22: 1073–7. 161 Russo R, Gilday D, Laxer RM, Eddy A, Silverman ED. Single photon emission computed tomography scanning in childhood systemic lupus erythematosus. J Rheumatol 1998; 25: 576–82. 162 Emmi L, Bramati M, De Cristofaro MT, Mascalchi M, Dal Pozzo G, Marconi GP, et al. MRI and SPECT investigations of the CNS in SLE patients. Clin Exp Rheumatol 1993; 11: 13–20. 163 Kodama K, Okada S, Hino T, Takabayashi K, Nawata Y, Uchida Y, et al. Single photon emission computed tomography in systemic lupus erythematosus with psychiatric symptoms. J Neurol Neurosurg Psychiatry 1995; 58: 307–11. 164 Rubbert A, Marienhagen J, Pirner K, Manger B, Grebmeier J, Engelhardt A, et al. Single-photon–emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1253–62. 165 Huang JL, Yeh KW, You DL, Hsieh KH. Serial single photon emission computed tomography imaging in patients with cerebral lupus during acute exacerbation and after treatment. Pediatr Neurol 1997; 17: 44–8. 166 Hanly JG. Evaluation of patients with CNS involvement in SLE. Baillieres Clin Rheumatol 1998; 12: 415–31. 167 Nossent JC, Hovestadt A, Schönfeld DHW, Swaak AJG. Single-photon–emission computed tomography of the brain in the evaluation of cerebral lupus. Arthritis Rheum 1991; 34: 1397–403. 168 Basoglu T, Ozbenli T, Bernay I, Sahin M, Onur A, Demircali AE, et al. Demonstration of frontal hypoperfusion in benign exertional headache by technetium-99m-HMPAO SPECT. J Nucl Med 1996; 37: 1172–4. 169 Afra J, Ertsey C, Jelencsik H, Dabasi G, Panczel G. SPECT and TCD studies in cluster headache patients. Funct Neurol 1995; 10: 259–64. 170 Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331: 1689–92. 171 Duncan R. Epilepsy, cerebral blood flow, and cerebral metabolic rate. Cerebrovasc Brain Metab Rev 1992; 4: 105–21. 172 Rodriguez G, Nobili F, De Carli F, Francione S, Marenco S, Celestino MA, et al. Regional cerebral blood flow in chronic stroke patients. Stroke 1993; 24: 94–9. Citing Literature Volume42, Issue10October 1999Pages 2026-2038 ReferencesRelatedInformation